Medibio Signs Memorandum of Understanding with DXC Technology for ilumen™

MELBOURNE, Australia – Medibio Limited (ASX: MEB)(OTCQB: MDBIF), a mental health technology company today announced that it has entered into a Memorandum of Understanding (MOU) with DXC Technology (NYSE: DXC), the world’s leading independent end-to-end IT services company, to establish a framework that identifies opportunities for Medibio’s corporate well-being product ilumen™, which offers participants early screening for symptoms of depression, anxiety, and stress.

The purpose of the MOU is to establish the framework for collaboration between Medibio and DXC to foster a strong working relationship that provides increased opportunities for the commercial success of ilumen™ in Australia, the US and worldwide. In particular, the MOU is intended to leverage and enhance the respective strengths of the sales and distribution channels for both parties, initially targeting tier-one mining, oil and gas clients with fly-in fly-out (FIFO) workforces who, studies have shown, are more likely to suffer from anxiety and depression than office-based workers.

The ilumen™ biometric data and subjective assessments provide users with a well-being snapshot to monitor and make improvements over time, whilst also providing management with de-identified aggregate data to better support and manage the mental well-being of their workforce.

Industry General Manager, Energy, Mining & Technology DXC Technology, Peter Swensen said: DXC is committed to improving the quality of the working lives of our clients employees. We are acutely aware of the increase in mental health issues impacting organisations and recognise that technology has a vital role to play. To this end, Medibio and DXC will work together to offer ilumen™ to explore opportunities that help address these issues.

DXC provides Australian businesses with best-in-class cloud, mobility, security, application development and modernisation, IT, workplace, big data analytics, and business process services across a range of industries. The company’s global scale and innovation platforms serve more than 6,000 private- and public-sector customers in 70 countries. Many of DXC’s customers are responsible for Australia’s infrastructure, defence and security while others are global leaders in banking, communications, manufacturing, retail, mining, energy and utilities.

Senior VP Corporate Health of Medibio Ltd, Jennifer Solitario said: We are delighted to be working with an organisation like DXC to identify opportunities for ilumen™ amongst their vast client base. DXC’s clients trust their technology-based solutions and services to run and transform their businesses and as such we are pleased to be collaborating with them. I look forward to a long and productive working relationship.

About DXC Technology
DXC Technology helps global companies run their mission critical systems and operations while modernising IT, optimising data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at

About Medibio
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on and